• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

MeMed wins $9.2m DoD deal for diagnostic device

April 19, 2017 By Sarah Faulkner

MeMed's 2nd-generation diagnostic deviceMeMed said today that it won a $9.2 million contract from the Defense Threat Reduction Agency, a branch of the U.S. Dept. of Defense, for its diagnostic platform that distinguishes bacterial infections from viral infections.

The Israel-based company has developed a test to recognize the distinct human immune signatures of both bacterial and viral infections – an important medical distinction since the 2 ailments require different methods of treatment.

“We are excited by this vote of confidence. DTRA’s recognition of our work further positions MeMed as a world leader in immune-based diagnostics of infectious diseases,” CEO Eran Eden said in prepared remarks.  “This joint effort, and our growing collaboration with other international stakeholders from industry and government, will facilitate the global availability of our tests aimed at combating antimicrobial resistance.”

The company’s 1st-gen device, ImmunoXpert, is in use and has been validated in thousands of patients, according to MeMed. The 2nd-gen test involved developing a new point-of-care platform that takes just 15 minutes.

“This collaboration will allow us to expedite completion of our point of care platform program,” CTO Dr. Kfir Oved added. “In addition to allowing measurements of our bacterial versus viral test within minutes, the new platform also opens the way to a variety of rapid multiplex-protein measurements at the point of care with lab-quality precision, which has broad applications.”

“The project will also evaluate and expand our test menu to detect early infections, even at the pre-symptomatic stage of a disease – currently a major challenge in our ability to control infections and epidemics,” VP of scientific affairs Tanya Gottlieb said.

Filed Under: Diagnostics, Featured, Funding Roundup Tagged With: memed, U.S. Defense Dept.

IN CASE YOU MISSED IT

  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS